Mystical experiences, marked by unity, transcendence, and a noetic quality, show therapeutic potential in clinical psychology. A new framework centers on the experience itself, requiring a non-ordinary state of consciousness for profound impact. It identifies three pre-state factors: invitation, context, and individual aptitude. After the experience, integration is a necessary mediating factor for beneficial change.
A standardized hypnosis intervention designed to produce a mystical experience was tested for feasibility and acceptability. Ten college students, all in the mid-to-high range of hypnotizability, received a hypnotic induction and suggestions for a mystical experience in a setting similar to psychedelic drug research. The intervention proved feasible and acceptable, with a composite acceptability score of 9.45, no dropouts, and all participants willing to participate again. Seventy percent of participants met criteria for a complete mystical experience on the Mystical Experience Questionnaire. The results are encouraging but require replication with a larger sample.
A critical review of six randomized controlled trials of MDMA-assisted therapy for PTSD finds that five show evidence of safety and efficacy. However, the review identifies serious methodological problems: lack of a suitable comparison condition, poor blinding, rigid trial designs, high treatment costs, and no head-to-head comparisons with established PTSD therapies. The sponsoring organization behind all trials may introduce bias. While the results are encouraging, there is not yet enough evidence to recommend widespread adoption of MDMA-assisted therapy over current validated treatments.